Imipenem/Cilastatin for the Treatment of Infections in Hospitalized Children

Gershon Alpert, Ron Dagan, Edward Connor, Joseph M. Campos, A. Michael Bloh, Keith R. Powell, Stanley A. Plotkin

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Imipenem is the first of a new class of βlactam antimicrobial agents with potent in vitro activity against most bacterial pathogens that cause infections in children. We studied, prospectively, the clinical efficacy and toxicity of imipenem/cilastatin in 40 children with proved or suspected bacterial infection. A dose of 100 mg/kg/day of imipenem was given to children younger than 3 years of age, while children older than 3 years of age received 60 mg/kg/day. Twenty-nine organisms were isolated from 26 patients. Infections treated included cellulitis, osteomyelitis, septic arthritis, lymphadenitis, renal infections, wound infections, and pneumonia. Bacteria isolated included Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Pseudomonas aeruginosa. All patients responded favorably to treatment, with defervescence and improvement of symptoms. All of the infecting bacteria were susceptible to imipenem. Imipenem/cilastatin was well tolerated, with no serious side effects, and appeared to be an effective and safe antimicrobial agent in the treatment of the population studied.

Original languageEnglish
Pages (from-to)1153-1156
Number of pages4
JournalAmerican Journal of Diseases of Children
Issue number11
StatePublished - 1 Jan 1985
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Imipenem/Cilastatin for the Treatment of Infections in Hospitalized Children'. Together they form a unique fingerprint.

Cite this